Chronic kidney disease (CKD) independently increases the rates of cardiovascular disease, whereas the severity of kidney disease correlates with increased cardiovascular morbidity and death. Vitamin D is modified in the liver and the kidney to its active form (1,25-dihydroxyvitamin D) by the 25-hydroxy vitamin D 1-hydroxylase enzyme (CYP27B1). The activated vitamin D brings about its actions through the vitamin D receptor (VDR). The VDRs and CYP27B1 have recently been shown to be expressed in several tissues, not directly involved in mineral homeostasis, including the cardiovascular, immune, and epithelial systems. The action of vitamin D in these tissues is implicated in the regulation of endothelial, vascular smooth muscle, and cardiac cell function, the renin-angiotensin system, inflammatory and fibrotic pathways, and immune response. Impaired VDR activation and signalling results in cellular dysfunction in several organs and biological systems, which leads to reduced bone health, an increased risk for epithelial cancers, metabolic disease, and uncontrolled inflammatory responses. Failure of cardiovascular VDR activation results in hypertension, accelerated atherosclerosis and vascular calcification, cardiac hypertrophy with vascular rarification and fibrosis, and progressive renal dysfunction. An emerging body of evidence has prompted attention to the relationship between CKD, mineral bone disorder (CKD-MBD), and cardiovascular disease in the new guidelines from Kidney Disease: Improving Global Outcomes. Vitamin D receptor activators, commonly used to treat CKD-MBD, and an appropriate treatment of vitamin D hormonal system failure in patients with CKD, may help to reduce cardiovascular morbidity and mortality in these patients.
Introduction
Chronic kidney disease (CKD) results in progressive kidney dysfunction characterized by diminished glomerular filtration rate (GFR), endocrine dysfunction, soft tissue calcification, and disrupted bone and mineral metabolism. 1 Secondary hyperparathyroidism (sHPT) and vitamin D deficiency are frequently present in patients with CKD and may also contribute to disease progression and cardiovascular disease-related morbidity and mortality. 2, 3 Substantial data in patients with CKD indicate that there is a close relationship between progressive renal dysfunction and cardiovascular disease and mortality. 4 -7 Furthermore, mortality in patients with moderate kidney dysfunction (measured by estimated GFR) is commonly associated with cardiovascular-related events ( Figure 1 ). 4 The prevalence of vitamin D deficiency among patients with CKD and its association with cardiovascular morbidity and mortality 2, 3, 8 suggests a potentially important link between low vitamin D levels and risks for cardiovascular events in this patient population. Data from a 5-year prospective longitudinal study involving more than 27 000 patients in the USA demonstrated that, in patients with CKD (defined as estimated GFR ,90 mL/min per 1.73 m 2 on two separate measurements at least 90 days apart), death is more likely than end-stage renal disease (ESRD) and that congestive heart failure (CHF) and coronary artery disease are more prevalent than haemodialysis in this patient population. 9 Furthermore, hypertension is cited as the second most common cause of ESRD after diabetes, 10 and arterial calcification is a complication of CKD. 5, 6 In light of this emerging evidence, the relationship between CKD-related mineral bone disorder and cardiovascular disease have been a focal point of the new guidelines from Kidney Disease: Improving Global Outcomes (KDIGO). 11 Although there appears to be an obvious link between vitamin D deficiency and increased cardiovascular risk, the mechanisms involved are not well understood. This article discusses the preclinical and clinical data that explore the potential mechanisms supporting the link between vitamin D deficiency, failure of the vitamin D hormonal system, vitamin D receptor (VDR) activator therapy, and cardiovascular disease.
Vitamin D hormonal system
Vitamin D is obtained as an inactive substance from dietary sources (vitamin D 2 , ergocalciferol) and from the action of sunlight on the skin (vitamin D 3 , cholecalciferol), and is metabolized from the inactive form (25-hydroxyvitamin D [25-D] ) to the active 1a,25-dihydroxyvitamin D 2 and D 3 (1,25-D) forms through enzymatic modification in the liver (25-hydroxylation) and kidney (1a-hydroxylation). 12, 13 Vitamin D mediates its effects via the VDR, a member of the steroid receptor superfamily. Vitamin D receptor is a ligand-activated transcription factor that forms a heterodimer with the retinoid X receptor, which results in the recruitment of other nuclear proteins to form the transcriptional pre-initiation complex. 14 Vitamin D receptors have been identified in over 30 human tissues, including the intestine, kidney, bone, parathyroid gland, immune system, smooth muscle, and myocardium. 15 Recent evidence demonstrates extrarenal expression of 25-D 1a-hydroxylase (CYP27B1) in several tissues, including hair follicles, lymph nodes, the tonsils, the colon, parasympathetic ganglia, the adrenal gland, the pancreas, the brain, 16 and the vasculature. 17 The selective VDR activation in multiple tissues ( Figure 2 ) explains the autocrine and paracrine actions of vitamin D, including those on the cardiovascular system. The binding of 1,25-D to the ubiquitously present VDR leads to activation of downstream endocrine, paracrine, and/or autocrine loops to maintain homeostasis in the kidney, bone, immune, and cardiovascular systems. 14 Holick and colleagues concluded that the synthesis, metabolism, and feedback loops of vitamin D and VDR have widespread systemic responses. 13, 18 Vitamin D receptor activation is increasingly recognized as a vital component in maintaining renal, cardiovascular, and bone tissue health.
25-Hydroxyvitamin D and 1a,25-dihydroxyvitamin D deficiency
Currently, there is no defined cut-off for deficiency of 25-D or 1,25-D; however, most studies have defined vitamin D deficiency as serum 25-D levels of ,20 ng/mL with normal levels .30 ng/ mL as desired. Vitamin D deficiency has been associated with several pathological states, including cancer, infectious diseases; Type 2 diabetes mellitus, hypertension, and cardiovascular disease. 8,18 -20 Several studies have shown survival benefit with vitamin D therapy in the general population, as well as in patients with CKD (pre-dialysis and dialysis; Table 1) . A meta-analysis of randomized trials evaluating the impact of ergocalciferol and cholecalciferol among patients with a variety of health conditions showed an association between supplemental vitamin D intake and reduced all-cause mortality rates. 21 Differential effects on mortality between types of VDR agonists were seen in a large, well-controlled historical cohort receiving IV paricalcitol (a synthetic 1,25-D analog, 19-nor-1,25-dihydroxyvitamin D 2 ) and IV calcitriol (synthetic 1,25-dihydroxyvitamin D 3 ) in the USA. 22 Paricalcitol was shown to confer improved 3-year survival in haemodialysis patients; a similar significant trend was observed in those who were switched from calcitriol to paricalcitol. 22 In comparison with calcitriol, doxercalciferol (a synthetic 1a-D, 1a-hydroxyvitamin D 2 ), and paricalcitol showed similar effects on mortality rates in haemodialysis patients. 23 To date, no studies have demonstrated increased mortality in patients receiving VDR agonist therapy. In addition, observational studies have noted a clinical advantage and cost reduction when VDR agonist therapies have been used. 24 -26 Studies demonstrating decreased mortality or hospitalization costs following VDR agonist therapy in patients with CKD are listed in Table 1 .
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The Accelerated Mortality on Renal Replacement (ArMORR) prospective, cross-sectional studies of 1,25-D and 25-D deficiencies in incident haemodialysis patients support the association between reduced mortality risk following the introduction Figure 3 ) and all-cause mortality by multivariate-adjusted analysis (odds ratio ¼ 0.60; 95% CI, 0.37 -0.91; P , 0.01). This association has been observed in patients with moderate renal impairment (Stage 3 -5 CKD, predialysis) and supports the use of VDR agonists in the early stages of CKD to lower mortality risk. 34, 35 The survival benefit with VDR agonist therapy needs to be further explored because a recent meta-analysis examining the effects of vitamin D therapy on mortality cited a lack of beneficial effect on patients. 36 However, there were a number of limitations to this study, notably the absence of inclusion of prospective studies and inability to directly compare older established therapies with newer, more selective treatments. The KDIGO initiative has the mission to create evidence-based guidelines for the diagnosis, evaluation, prevention, and management of CKD; this effort currently includes the classification of Stages 1-5 CKD with an updated perspective on the pathophysiology of CKD as it relates to renal and extrarenal pathways for vitamin D actions and effects.
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Studies in animals and humans have found that vitamin D hormonal regulation in CKD is not driven solely by parathyroid hormone (PTH) levels and renal phosphate metabolism. Shimada et al. performed an in vivo experimental study to evaluate the effects of fibroblast growth factor-23 (FGF-23) on phosphate and 1,25-D metabolism, which included a control group of animals subjected to parathyroidectomy (PTX), and found that FGF-23 reduced serum phosphate and 1,25-D levels even in the PTX animals. These effects were independent of renal phosphate reabsorption and thought to be associated with possible extrarenal mechanisms. 37 Vitamin D deficiency and the cardiovascular system Cardiovascular morbidity and mortality Numerous epidemiological and clinical studies have suggested a strong association between vitamin D deficiency and cardiovascular disease in the general population. 38 The various cardiovascular effects of vitamin D deficiency and reduced VDR activation include hypertension, vascular calcification, smooth muscle cell Figure 3 Odds ratio by multivariate-adjusted (covariates used in multivariate models included age, gender, race, aetiology of renal failure, blood pressure, body mass index, dialysis access at initiation, dialysis dose, facility-specific standardized mortality rates, and co-morbidities at the initiation of dialysis) analysis for 90-day cardiovascular mortality in haemodialysis patients according to baseline (A) 25 
Blood pressure
High blood pressure is a well-characterized independent risk factor for cardiovascular disease. The renin-angiotensin system (RAS) is a key regulator of blood pressure and is implicated as a mechanism for hypertension in vitamin D deficiency. Preclinical studies of the RAS confirm its involvement in regulating blood pressure and volume homeostasis to modulate cardiovascular and renal outcomes. Renin synthesis, the first and rate-limiting component of the RAS cascade, increased several-fold in the juxtaglomerular cells of VDR knockout mice with concomitant plasma RAS activation; VDR activation of RAS was independent of calcium and PTH. 46, 47 Treatment of experimental models of CKD 48 and diabetic nephropathy 49 with angiotensin-converting enzyme inhibitor or angiotensin receptor II blocker and VDR agonist paricalcitol effectively prevented progression of kidney disease, mirroring the effect of aliskiren, a new oral direct renin inhibitor.
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In VDR-null mice, renin mRNA was more than three times higher and plasma levels of angiotensin II were more than 2.5 times higher than in wild-type mice. Interestingly, despite higher renin mRNA expression, the VDR-null mice response to salt loading and dehydration was the same for wild-type mice, suggesting that the mechanism of VDR activity on blood pressure was separate from the physiological effects of changes in renal tubular salt load and volume depletion. 51 A recent study showed that plasma 25-D levels inversely correlate with the risk of incident hypertension. 52 The analyses of data from 12 644 subjects in the third National Health and Nutrition Examination Survey (NHANES) demonstrated a modest but significant inverse correlation between serum 25-D levels and blood pressure after adjustment for age, gender, ethnicity, and physical activity. 53 Possible relationships between vitamin D and arterial dysfunction were evaluated in stable patients with ESRD who were on haemodialysis. Aortic pulse wave velocity (PWV), brachial artery distensibility (BAD), flow-mediated distensibility (FMD), and arterial calcification were measured, and 1,25-D levels were determined using radioimmunoassay. Univariate analyses found a negative correlation between 1,25-D and PWV (20.616, P , 0.0001) and positive correlations between 1,25-D and BAD (0.632, P , 0.01) and FMD (0.741, P , 0.0001), but no correlation between 1,25-D and arterial calcification. 54 
Vascular calcification
Vascular calcification is a common manifestation of cardiovascular disease in patients with CKD, and serum 1,25-D levels have been shown to inversely correlate with vascular calcification. 55 A subanalysis among patients without baseline coronary artery calcification from the Multi-Ethnic Study of Atherosclerosis demonstrated that low 25-D levels were associated with an increased risk for coronary artery calcification, independent of other cardiovascular disease risk factors over a 3-year follow-up period. 56 The impact of VDR agonists on vascular calcification is variable depending on the dose administered. 57, 58 Low or clinically relevant doses of VDR agonists correlate with decreased deposition of calcium and improved therapeutic outcomes, whereas high doses may actually induce vascular calcification, 59, 60 an effect that is reversible with the cessation of treatment and probably indirectly mediated by hypercalcaemia and hyperphosphataemia. 61 In contrast to the potentially harmful effects of vascular calcification observed following high doses of VDR agonists, 60 VDR activation has a number of potential ameliorative effects on both inhibitors and inducers of calcification ( Figure 2 ).
Myocardial effects
There is growing evidence to suggest an inversely proportional association of low vitamin D levels and myocardial infarction. Patients with CKD are deficient in both 25-D and 1,25-D, which are associated with arterial parameters of increased PWV and arterial stiffness along with elevated LVH and cardiovascular mortality in dialysis patients. 32, 54 Treatment with a VDR agonist has been associated with reduced LVH in haemodialysis patients, without causing effects on heart rate, blood pressure, or total peripheral resistance. 68 
Proteinuria and albuminuria
Microalbuminuria and macroalbuminuria have been identified as risk factors for cardiovascular death. Therapies that reduce proteinuria demonstrate notable cardioprotective and renoprotective responses. 69 -72 In the Reduction of Endpoints in Non-Insulin-Dependent Diabetes Mellitus (NIDDM) With the Angiotensin II Antagonist Losartan (RENAAL) study, baseline albuminuria was shown to be a determinant risk for cardiac events in patients with renal events, regardless of the initiating complication (cardiovascular or renal). 73 Data from the Prevention of Renal and Vascular End-Stage Disease (PREVEND) study, a large postal questionnaire study, demonstrated that urinary albumin excretion is a predictor of all-cause and cardiovascular mortality in the general population ( Figure 4) . 74 Reduced proteinuria has been observed with exogenous 1,25-D 3 treatment in animal models independent of its PTH-lowering effects, 75 as well as in patients with Stage 3/4
CKD with sHPT treated with paricalcitol despite the use of reninangiotensin -aldosterone system inhibitors, 76 and in patients with immunoglobulin A nephropathy following calcitriol treatment. 77 Agarwal et al. 76 reported a reduction in proteinuria in 51% of patients with CKD treated with oral paricalcitol compared with 25% of those who received placebo (P ¼ 0.004). 80 Hypercalcaemia affects a number of pathological processes and is associated with vascular calcification and the development of cardiovascular disease. 81 -84 These findings reiterate the need to monitor patients and ensure proper maintenance of calcium and phosphorus, thus providing optimal therapy in what appears to be a relatively narrow therapeutic window of endocrine effects for exogenous, non-selective VDR agonists, such as Figure 4 Hazard ratio (The effects of urinary albumin concentration on cause-specific hazards of cardiovascular risk were calculated using a
Implications and limitations for clinical practice
Cox proportional-hazards model adjusted for explanatory variables, which included sex, age, presence of diabetes mellitus, use of antihypertensive drugs, use of lipid-lowering drugs, smoking, family history of cardiovascular disease, previous myocardial infarction, previous stroke, and urinary albumin concentration doubling.) for cardiovascular death by urinary albumin concentration: PREVEND study (reproduced with permission from Hillege et al. 74 ). UAC, urinary albumin concentration.
calcitriol, and prodrugs that require activation in the liver (e.g. 
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